{"url_path":"/sec/lpcn/8-k/2026-05-19/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1535955/0001493152-26-024365-index.html","accession_number":"0001493152-26-024365","cik":"0001535955","ticker":"LPCN","issuer_name":"Lipocine Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1535955/0001493152-26-024365-index.html","primary_entity_key":"0001535955","primary_entity_name":"Lipocine Inc."},"word_count":58,"has_tables":true,"body_markdown":"**Item\n8.01**\n**Other\nEvents**\n\n \n\nOn\nMay 19, 2026, the Company issued a press release announcing Lipocine’s LPCN 1154 Phase 3 data has been accepted for oral presentation\nat the 2026 ASCP Annual Meeting to be held May 26-29, 2026, in Miami, Florida. The press release is furnished as Exhibit 99.1 to this\nreport and incorporated by reference herein."}